[A17-06] Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 15.05.2017
Project no.:
A17-06
Commission:
Commission awarded on 10.02.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2017-08-03 A G-BA decision was published.
G-BA documents on this decision
Federal Joint Committee (G-BA)
2017-08-03 A G-BA decision was published.